Dengyong Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dengyong Xu has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Da Wang
Department of Colorectal Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, P.R. China
2 shared publications - Chuanxi Lai
Department of Colorectal Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
1 shared publication Da Man
Department of Colorectal Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, P.R. China
1 shared publication- David W. Larson
Department of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN
1 shared publication - Fei Wang
Department of Colorectal Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
1 shared publication - Feixiang Zhang
Department of Colorectal Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
1 shared publication
Latest Publications
- Open Access
- 27 October 2026
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 32 (6) , 1-9
5‑Fluorouracil‑induced severe hyperlactatemic encephalopathy during chemotherapy for advanced colorectal cancer: Case reports and literature review
5‑Fluorouracil (5‑FU) is a key drug in the treatment of advanced colorectal cancer (CRC). Although 5‑FU is generally well tolerated, a small subset of patients may experience life‑threatening neurotoxicity. Among these complications, 5‑FU‑induced encephalopathy accompanied by severe hyperlactatemia is a particularly serious metabolic emergency. Impaired drug clearance, especially due to underlying renal insufficiency, may substantially increase this risk. In the present study, the cases of three patients with advanced CRC who developed acute, severe impairment of consciousness 48 h after receiving 5‑FU‑based chemotherapy were retrospectively reviewed. Clinical presentations ranged from aphasia and confusion to deep coma. All patients exhibited marked hyperlactatemia, with peak blood lactate levels of 18.0, 18.19 and 15.56 mmol/l for Cases 1, 2 and 3, respectively. A total of two patients had marked baseline renal impairment (one with chronic kidney disease, the other with end‑stage renal disease on maintenance hemodialysis). Neuroimaging (CT/CT perfusion/CT angiography/MRI) excluded acute cerebrovascular events in all cases. Chemotherapy was immediately discontinued and intensive supportive care was initiated. For the patient with anuric renal failure, early continuous venovenous hemofiltration was initiated. All three patients achieved complete neurological recovery and normalization of metabolic parameters. Notably, the hemodialysis‑dependent patient subsequently underwent successful 5‑FU rechallenge using a 50% dose reduction combined with prophylactic post‑chemotherapy hemodialysis, without recurrence of neurotoxicity. 5‑FU‑induced severe hyperlactatemic encephalopathy is a potentially fatal oncological emergency. Underlying renal impairment may lead to the accumulation of toxic metabolites. For patients presenting with extreme hyperlactatemia (>10 mmol/l) and profound impairment of consciousness, early initiation of continuous renal replacement therapy may be an effective strategy to resolve neurological dysfunction. In patients with end‑stage renal disease requiring subsequent fluoropyrimidine therapy, substantial dose reduction combined with prophylactic hemodialysis may offer a feasible rechallenge approach. Furthermore, clinicians must consider genetic mutations related to hepatotoxicity and nephrotoxicity. Evaluation of these organ‑vulnerability genes before chemotherapy warrants further clinical investigation to prevent severe toxicity.
- 27 October 2026
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 32 (6) , 1-9
Open Access5‑Fluorouracil‑induced severe hyperlactatemic encephalopathy during chemotherapy for advanced colorectal cancer: Case reports and literature review
5‑Fluorouracil (5‑FU) is a key drug in the treatment of advanced colorectal cancer (CRC). Although 5‑FU is generally well tolerated, a small subset of patients may experience life‑threatening neurotoxicity. Among these complications, 5‑FU‑induced encephalopathy accompanied by severe hyperlactatemia is a particularly serious metabolic emergency. Impaired drug clearance, especially due to underlying renal insufficiency, may substantially increase this risk. In the present study, the cases of three patients with advanced CRC who developed acute, severe impairment of consciousness 48 h after receiving 5‑FU‑based chemotherapy were retrospectively reviewed. Clinical presentations ranged from aphasia and confusion to deep coma. All patients exhibited marked hyperlactatemia, with peak blood lactate levels of 18.0, 18.19 and 15.56 mmol/l for Cases 1, 2 and 3, respectively. A total of two patients had marked baseline renal impairment (one with chronic kidney disease, the other with end‑stage renal disease on maintenance hemodialysis). Neuroimaging (CT/CT perfusion/CT angiography/MRI) excluded acute cerebrovascular events in all cases. Chemotherapy was immediately discontinued and intensive supportive care was initiated. For the patient with anuric renal failure, early continuous venovenous hemofiltration was initiated. All three patients achieved complete neurological recovery and normalization of metabolic parameters. Notably, the hemodialysis‑dependent patient subsequently underwent successful 5‑FU rechallenge using a 50% dose reduction combined with prophylactic post‑chemotherapy hemodialysis, without recurrence of neurotoxicity. 5‑FU‑induced severe hyperlactatemic encephalopathy is a potentially fatal oncological emergency. Underlying renal impairment may lead to the accumulation of toxic metabolites. For patients presenting with extreme hyperlactatemia (>10 mmol/l) and profound impairment of consciousness, early initiation of continuous renal replacement therapy may be an effective strategy to resolve neurological dysfunction. In patients with end‑stage renal disease requiring subsequent fluoropyrimidine therapy, substantial dose reduction combined with prophylactic hemodialysis may offer a feasible rechallenge approach. Furthermore, clinicians must consider genetic mutations related to hepatotoxicity and nephrotoxicity. Evaluation of these organ‑vulnerability genes before chemotherapy warrants further clinical investigation to prevent severe toxicity.
- Open Access
- 2 August 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (1) , 334-345
Efficacy and safety of combining short-course neoadjuvant chemoradiotherapy with envafolimab in locally advanced rectal cancer patients with microsatellite stability: a phase II PRECAM experimental study
Background: Conventional neoadjuvant chemoradiotherapy (nCRT) yields a pathologic complete response (pCR) rate of 15–30% for locally advanced rectal cancer (LARC). This study ventures to shift this paradigm by incorporating short-course nCRT with immunotherapy, specifically Envafolimab, to achieve improved treatment efficacy and possibly redefine the standard of care for LARC. Materials and methods: The PRECAM study is a prospective, single-arm, phase 2 clinical trial for LARC in patients with microsatellite stable (MSS) tumors. Participants received short-course radiotherapy (25Gy/5f), followed by two cycles of CAPEOX chemotherapy and six weekly doses of Envafolimab, a PD-L1 antibody, before total mesorectal excision surgery. The primary endpoint was the pCR rate. Results: From April to December 2022, 34 patients were enrolled, of whom 32 completed the study, each diagnosed with an MSS rectal adenocarcinoma. All patients underwent preoperative CRT combined with Envafolimab. Remarkably, a pCR rate of 62.5% (20/32) was attained, and a significant pathologic response rate of 75% (24/32) was achieved. Additionally, 21 of 32 participants achieved a neoadjuvant rectal (NAR) score below 8, suggesting an effective treatment response. Common adverse events included tenesmus (78.1%), diarrhea (62.5%), and leukocyte decrease (40.6%). Two Grade 3 adverse events were noted, one related to liver function abnormality and the other to a decrease in platelet count. Surgical procedures were performed in all cases, with minor complications, including ileus, infections, and anastomotic leakage. As of this report, there have been no reported cases of recurrence or death during the follow-up period, ranging from 12 to 20 months. Conclusion: In LARC patients exhibiting MSS tumors, combining short-course nCRT with Envafolimab demonstrated favorable efficacy, leading to a significant pCR rate. Minor adverse effects and surgical complications were observed. These preliminary but promising results underscore the potential of this approach and call for further exploration and validation through a randomized controlled trial.
- 2 August 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (1) , 334-345
Open AccessEfficacy and safety of combining short-course neoadjuvant chemoradiotherapy with envafolimab in locally advanced rectal cancer patients with microsatellite stability: a phase II PRECAM experimental study
Background: Conventional neoadjuvant chemoradiotherapy (nCRT) yields a pathologic complete response (pCR) rate of 15–30% for locally advanced rectal cancer (LARC). This study ventures to shift this paradigm by incorporating short-course nCRT with immunotherapy, specifically Envafolimab, to achieve improved treatment efficacy and possibly redefine the standard of care for LARC. Materials and methods: The PRECAM study is a prospective, single-arm, phase 2 clinical trial for LARC in patients with microsatellite stable (MSS) tumors. Participants received short-course radiotherapy (25Gy/5f), followed by two cycles of CAPEOX chemotherapy and six weekly doses of Envafolimab, a PD-L1 antibody, before total mesorectal excision surgery. The primary endpoint was the pCR rate. Results: From April to December 2022, 34 patients were enrolled, of whom 32 completed the study, each diagnosed with an MSS rectal adenocarcinoma. All patients underwent preoperative CRT combined with Envafolimab. Remarkably, a pCR rate of 62.5% (20/32) was attained, and a significant pathologic response rate of 75% (24/32) was achieved. Additionally, 21 of 32 participants achieved a neoadjuvant rectal (NAR) score below 8, suggesting an effective treatment response. Common adverse events included tenesmus (78.1%), diarrhea (62.5%), and leukocyte decrease (40.6%). Two Grade 3 adverse events were noted, one related to liver function abnormality and the other to a decrease in platelet count. Surgical procedures were performed in all cases, with minor complications, including ileus, infections, and anastomotic leakage. As of this report, there have been no reported cases of recurrence or death during the follow-up period, ranging from 12 to 20 months. Conclusion: In LARC patients exhibiting MSS tumors, combining short-course nCRT with Envafolimab demonstrated favorable efficacy, leading to a significant pCR rate. Minor adverse effects and surgical complications were observed. These preliminary but promising results underscore the potential of this approach and call for further exploration and validation through a randomized controlled trial.